Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Status unconfirmed · Phase 2

Conditions studied: Myelodysplastic Syndromes

In brief

RATIONALE: Monoclonal antibodies such as gemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial to study the effectiveness of gemtuzumab in treating patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00022321

Run by

Jonsson Comprehensive Cancer Center

Starts

2001-09-01

Last updated by the study team

2013-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.